Cellectis S.A.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Cellectis
Biological Products, (No Diagnostic Substances), SIC 2836
The provided text consists entirely of raw XBRL tags, taxonomy identifiers, financial line item members, and dates, with no narrative business disclosure. The metadata references entities such as Cellectis, Cellectis Biologics, and Calyxt, along with collaboration agreements involving AstraZeneca and Servier. However, the text does not contain any descriptive sentences outlining what the company does, its specific products, operating segments, or customer base.
The excerpt also lacks descriptive text regarding the company's operational scale, geographic footprint, store or facility counts, and headquarters location. It only includes jurisdiction tags for France and the United States alongside lease and loan accounting entries, without stating where the corporate headquarters is located or detailing any physical operations.
Summary of the business section of Cellectis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cellectis S.A.
- Founded
- 1999
- Headquarters
- Paris, Lle-De-France, France
- Address
- 8 Rue De La Croix Jarry
- Phone
- 33181691600
- Website
- www.cellectis.com
- Employees
- 229, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- I0
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young et Autres, Courbevoie, France
Stock & identifiers
- Ticker
- CLLS
- Exchange
- Nasdaq
- Shares outstanding
- 100M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1627281
- CUSIP
- 15117K103
- ISIN
- US15117K1034
- LEI
- 5493000KKX5VQ37Q2W83
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Cellectis's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 229 employees, 224 of whom were full-time, 58 of whom hold M.D, Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 23, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |